Aneta Nowicka

Mrs. Aneta Nowicka

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 July 2025 in Biomedicines
Verified
Journal Article
Open access
PDF file
ANAneta Nowicka
Aneta Nowicka
HTHanna Tomczak
Hanna Tomczak
ESEdyta Szałek
Edyta Szałek
AKAgnieszka Karbownik
Agnieszka Karbownik
LGLidia Gil
Lidia Gil
Increasing evidence demonstrates the mutualistic connection between the microbiome and acute myeloid leukemia (AML) treatment. Drugs disrupt the microbial balance and, conversely, changes in the microbiome influence therapy. A new field, pharmacomicrobiomics, examines the role of the microbiome in pharmacokinetics, pharmacodynamics, and drug toxicity. The multimodal therapeutic management of AML, along with disease-related immunosuppression, infection, and malnutrition, creates the unique microbial profile of AML patients, in which every delicate modification plays a crucial role in pharmacotherapy. While both preclinical and real-world data have confirmed a bilateral connection between standard chemotherapy and the microbiome, the impact of novel targeted therapies and immunotherapy remains unknown. Multi-omics technologies have provided qualitative and mechanistic insights into specific compositional and functional microbial signatures associated with the outcomes of AML therapy, but require a large-scale investigation to draw reliable conclusions. In this review, we outline the role of the microbiome within the therapeutic landscape of AML, focusing on the determinants of post-treatment dysbiosis and its effects on the therapeutic response and toxicity. We explore emerging strategies for microbiota modulation, highlighting their safety and efficacy. Advances in microbiome-based approaches are an inevitable step toward precision medicine in AML. However, clinical research in a well-defined group of immunocompromised patients is needed to study their variable effects on human health and determine safety issues.

31 January 2026 in International Journal of Infectious Diseases
Verified
Journal Article
Open access
ANAneta Nowicka
Aneta Nowicka
LGLidia Gil
Lidia Gil
Colonization with carbapenem-resistant Pseudomonas spp (CRP) contributes to infections and high mortality. Fecal microbiota transplantation (FMT) offers a strategy for eradicating multidrug-resistant organisms, but experience on CRP decolonization in immunocompromised patients is meagre. A single-center retrospective study of gastroscopic FMT in CRP-positive hematological patients. The primary objective was decolonization. Short and long-term post-FMT CRP-related infectious complications were evaluated. By April 30, 2025, 14 patients (5 ALL, 5 AML, 2 MDS, 1 APL, 1 NHL) were enrolled; 8 had received allo-HCT. With a median follow-up of 16 months (1.45-26), decolonization was achieved in 10 in a median of 14 days (9-34) and was durable in 6. Eradication failure occurred in 4 due to persistence and 4 due to recurrence. Median time to recolonization was 83 (32-173). 9 patients experienced CRP-related infections following FMT: bloodstream infections (BSI) 67%, soft tissue 56%, gastrointestinal 56%, urinary tract 33%, pneumonia 22%, septic shock 22%. A total of 7 died; due to infections in 6, with CRP responsible in 5. No severe adverse events of FMT were reported. FMT demonstrates safety and efficacy in early decolonization of CRP. In failure, CRP-related infections remain a leading cause of mortality.

21 October 2024 in Advances in Clinical and Experimental Medicine
Verified
Journal Article
Open access
ANAneta Nowicka
Aneta Nowicka
LGLidia Gil
Lidia Gil
Acute myeloid leukemia (AML), the most common leukemia in adults, is a biologically heterogeneous disease arising from clonally proliferating hematopoietic stem cells. Increased appreciation of novel genetic methods has improved the understanding of AML biology. Recently, the emerging field of metabolomics has indicated qualitative and quantitative alterations in metabolic profiles in AML pathogenesis, progression and treatment. Multiple metabolic and molecular pathways regulate human metabolism and host-microbiome interactions may significantly affect this biochemical machinery. Microbiota have been found to play a significant role in hematopoietic function, metabolism and immunity, contributing to AML occurrence. A large number of studies have highlighted the importance of the composition and diversity of the gut microbiota (GM) in response to treatment and prognosis in AML. Moreover, strong evidence emphasizes the detrimental link between dysbiosis and infectious complications, a leading cause of morbidity and mortality for patients with AML. Several microbiota-related mechanisms have been linked to particular changes in host physiology so far, and microbial-derived metabolites belong to one of the most important. Circulating in the body, they modulate human conditions both locally and systemically. The extensive and diverse repertoire of bacterial metabolic functions plays a critical role in numerous processes, including leukemogenesis. Integrative analysis of microbiome and metabolome data is a promising avenue for better understanding the complex relationship between the microbiota, biochemical alterations and AML pathogenesis to effectively prevent, treat and mitigate its outcomes. This review concentrates on the pathologic roles and therapeutic implications of microbe-derived metabolites in AML settings.

15 October 2026 in Annals of Hematology
Verified
Journal Article
Open access
PDF file
ANAneta Nowicka
Aneta Nowicka
ASAnna Sowinska
Anna Sowinska
BWBarbara Więckowska
Barbara Więckowska
LGLidia Gil
Lidia Gil
We evaluated the 13-year (2012–2025) evolution of infectious epidemiology in a Polish acute myeloid leukemia (AML) induction cohort, contextualizing these findings within shifting antimicrobial resistance (AMR), the SARS-CoV-2 pandemic, changing prophylaxis protocols (including fluoroquinolone cessation), and evolving diagnostic methodologies. Secondarily, we compared historical standard induction therapy (SIT) and novel targeted induction (NIT) regimens. This exploratory, retrospective, single-center study assessed induction-related infections in 219 newly diagnosed AML adults. We observationally evaluated temporal shifts in etiology and AMR, utilizing an interrupted time series approach to assess the 2018 cessation of universal fluoroquinolone prophylaxis, alongside a secondary comparison of SIT (n=189) and NIT (n=30) cohorts. The evolving infectious etiology in AML is driven by temporal, diagnostic, and ecological transitions rather than novel agents. Halting fluoroquinolone prophylaxis was clinically safe. Integrating contemporary therapies requires continuously adapting supportive frameworks to local epidemiology.Overall 30-day mortality was 8.2%. Comparing the pre-2018 (active fluoroquinolone) and post-2018 (discontinued) eras, proportional bloodstream infections (BSI; 40.6% vs. 34.7%) and multidrug-resistant organism (MDRO) rates (77.2% vs. 68.6%) decreased, without a compensatory Gram-negative surge. Concurrently, 30-day mortality dropped from 11.9% to 5.1%. Between NIT and SIT, incidences of microbiologically documented infections (53.3% vs. 51.3%), invasive fungal diseases (6.7% vs. 13.2%), and BSI (33.3% vs. 38.1%) were comparable. The higher incidence of VIM-producing Pseudomonas aeruginosa (30.8% vs. 3.3%; p=0.005) and SARS-CoV-2 (53.3% vs. 33.3%; p=0.034) in NIT was confounded by total overlap with the pandemic era and advanced molecular diagnostics. The evolving infectious etiology in AML is driven by temporal, diagnostic, and ecological transitions rather than novel agents. Halting fluoroquinolone prophylaxis was clinically safe. Integrating contemporary therapies requires continuously adapting supportive frameworks to local epidemiology.